Aliases & Classifications for Myofibroma

MalaCards integrated aliases for Myofibroma:

Name: Myofibroma 12 43 15 17 71
Solitary Myofibromatosis 71
Uterine Fibroids 71
Lipoleiomyoma 12
Myolipoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4386
MeSH 43 D047708
SNOMED-CT 67 128917003
UMLS 71 C0042133 C1096309 C1266121 more

Summaries for Myofibroma

MalaCards based summary : Myofibroma, also known as solitary myofibromatosis, is related to pleomorphic lipoma and leiomyoma, and has symptoms including pelvic pain An important gene associated with Myofibroma is RELA (RELA Proto-Oncogene, NF-KB Subunit), and among its related pathways/superpathways is Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Leuprolide and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and prostate, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Myofibroma

Diseases related to Myofibroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 pleomorphic lipoma 30.9 SERPINA3 CD34
2 leiomyoma 30.8 S100A1 DES CD34
3 myopericytoma 30.5 SRF RELA PDGFRB
4 epulis 30.4 SERPINA3 DES
5 infantile myofibromatosis 30.4 PDGFRB MIR143 MB ETV6 DES CD34
6 lipomatosis, multiple 30.3 SERPINA3 DES CD34 CALD1
7 neurofibroma 30.3 S100A1 F13A1 CD34
8 intravenous leiomyomatosis 30.1 DES CD34 CALD1
9 liposarcoma 30.0 MYOG MB DES CD34
10 glomus tumor 29.8 S100A1 DES CD34 CALD1
11 fibroma 29.6 SERPINA3 S100A1 F13A1 DES CD34
12 rhabdomyosarcoma 29.5 PDGFRB MYOG MB DES
13 horner's syndrome 29.4 MYOG DES
14 hemangiopericytoma, malignant 29.2 SERPINA3 MYOG F13A1 DES CD34 CALD1
15 well-differentiated liposarcoma 29.2 SERPINA3 MYOG CD34 CALD1
16 spindle cell sarcoma 29.1 SERPINA3 MYOG DES CD34
17 neurilemmoma 29.1 SERPINA3 S100A1 PDGFRB DES CD34
18 sarcoma, synovial 29.1 SERPINA3 MYOG DES CD34
19 pseudosarcomatous fibromatosis 29.0 SERPINA3 MYOG DES CD34 CALD1
20 connective tissue benign neoplasm 29.0 SERPINA3 PDGFRB CD34 CD1A CALD1
21 ewing sarcoma 28.9 PDGFRB MYOG DES CD34
22 smooth muscle tumor 28.9 SERPINA3 S100A1 MIR143 DES CD34 CALD1
23 congenital fibrosarcoma 28.8 SERPINA3 S100A1 MYOG ETV6 DES
24 mesenchymal cell neoplasm 28.8 SERPINA3 PDGFRB MYOG CD34 CALD1
25 fibrous histiocytoma 28.8 SERPINA3 MYOG F13A1 DES CD34
26 leiomyosarcoma 28.8 SERPINA3 S100A1 PDGFRB MYOG MB DES
27 sarcoma 28.6 SERPINA3 S100A1 PDGFRB MYOG DES
28 uterine corpus lipoleiomyoma 12.3
29 curry-jones syndrome 11.5
30 giant cell myocarditis 10.5 MB DES
31 fibroblastic rheumatism 10.5 F13A1 DES
32 ischemic fasciitis 10.5 S100A1 DES
33 alk+ histiocytosis 10.4 F13A1 CD1A
34 fibromatosis 10.4
35 exophthalmos 10.4
36 parachordoma 10.4 S100A1 DES
37 reticulum cell sarcoma 10.4 S100A1 DES
38 cutaneous leiomyosarcoma 10.4 DES CALD1
39 granuloma annulare 10.4 F13A1 CD1A
40 cellular leiomyoma 10.4 DES CALD1
41 ossifying fibromyxoid tumor 10.4 S100A1 DES
42 cystic teratoma 10.3
43 teratoma 10.3
44 congenital epulis 10.3 SERPINA3 DES
45 verruciform xanthoma of skin 10.3 SERPINA3 CD1A
46 erythema elevatum diutinum 10.3 F13A1 CD34
47 syringocystadenoma papilliferum 10.3 SERPINA3 DES
48 reticulohistiocytic granuloma 10.3 SERPINA3 CD1A
49 orbital cancer 10.3 CD34 CD1A
50 leiomyoma, uterine 10.3

Comorbidity relations with Myofibroma via Phenotypic Disease Network (PDN):


Asherman's Syndrome Cervix Uteri Carcinoma in Situ
Chronic Salpingo-Oophoritis Endometriosis
Endometriosis of Ovary Female Stress Incontinence
Hemometra Ovarian Cancer
Salpingo-Oophoritis

Graphical network of the top 20 diseases related to Myofibroma:



Diseases related to Myofibroma

Symptoms & Phenotypes for Myofibroma

UMLS symptoms related to Myofibroma:


pelvic pain

GenomeRNAi Phenotypes related to Myofibroma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CD1A CD34 DES ETV6 F13A1 SRF

MGI Mouse Phenotypes related to Myofibroma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.81 CD34 DES ETV6 MB MYOG PDGFRB
2 homeostasis/metabolism MP:0005376 9.7 CD34 DES ETV6 F13A1 MB MYOG
3 muscle MP:0005369 9.17 DES MB MYOG PDGFRB RELA S100A1

Drugs & Therapeutics for Myofibroma

Drugs for Myofibroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
2
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
3
Dienogest Approved Phase 4 65928-58-7
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Ferrous fumarate Approved Phase 4 141-01-5
6
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
9
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
10
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
11
Zinc oxide Approved Phase 4 1314-13-2
12
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
13
Calcium carbonate Approved, Investigational Phase 4 471-34-1
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
17
Goserelin Approved Phase 4 65807-02-5 5311128 47725
18
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Dinoprostone Approved Phase 4 363-24-6 5280360
21
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
22
Morphine Approved, Investigational Phase 4 57-27-2 5288826
23
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
26
Misoprostol Approved Phase 4 59122-46-2 5282381
27
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
28
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
29
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
30
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
31
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
32
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
35
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
38
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
39
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
40
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
41
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
43
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
46
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
47
Cobalamin Experimental Phase 4 13408-78-1 6857388
48
Fibrinolysin Investigational Phase 4 9004-09-5
49 Ulipristal acetate Phase 4 126784-99-4
50 Contraceptive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 340)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
3 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
4 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
5 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
6 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
7 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
8 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
9 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
10 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
11 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
12 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
13 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
14 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
15 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
16 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
17 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
18 Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Completed NCT03308643 Phase 4 Oxytocin
19 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
20 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
21 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
22 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
23 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
24 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
25 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
26 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
27 Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women - 2018 Recruiting NCT04043520 Phase 4 GnRH antagonist;Estrogen Product;Placebo estradiol;Placebo GnRH antagonist
28 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
29 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
30 Effect of Transversus Abdominal Plane Block Using Liposomal Bupivacaine Versus Standard Bupivacaine for Open Myomectomy: A Prospective Randomized Control Trial Not yet recruiting NCT04272086 Phase 4 Bupivacaine;Bupivacaine liposome;normal saline
31 Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Not yet recruiting NCT04364581 Phase 4 Letrozole;Placebo
32 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
33 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
34 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
35 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Terminated NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
36 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
37 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
38 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
39 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
40 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
41 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
42 Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns Unknown status NCT01280045 Phase 3
43 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
44 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Unknown status NCT03483142 Phase 3 Misoprostol;Placebos
45 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
46 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
47 Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT02925494 Phase 3 Estradiol/Norethindrone Acetate;Elagolix
48 Uterine Fibroids: Impact of Ulipristal Acetate 10 mg on ART Results Completed NCT02425878 Phase 3 Ulipristal Acetate;Placebo
49 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02654054 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
50 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02691494 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix

Search NIH Clinical Center for Myofibroma

Cochrane evidence based reviews: myofibroma

Genetic Tests for Myofibroma

Anatomical Context for Myofibroma

MalaCards organs/tissues related to Myofibroma:

40
Uterus, Breast, Prostate, Bone, Smooth Muscle, Liver, Skin

Publications for Myofibroma

Articles related to Myofibroma:

(show top 50) (show all 3077)
# Title Authors PMID Year
1
Response to comment on: Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids. 61
32444256 2020
2
Comment on: Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids. 61
32499104 2020
3
Comparison of Focused Ultrasound Surgery and Hysteroscopic Resection for Treatment of Submucosal Uterine Fibroids (FIGO Type 2). 61
32359807 2020
4
Development and clinical evaluation of a 3-step modified manipulation protocol for MRI-guided high-intensity focused ultrasound of uterine fibroids. 61
32166489 2020
5
From 2646 to 15: differentially regulated microRNAs between progenitors from normal myometrium and leiomyoma. 61
31874141 2020
6
Influence of Ethnicity on Clinical Presentation and Quality of Life in Women With Uterine Fibroids: Results From a Prospective Observational Registry. 61
31882290 2020
7
Use of a microsurgical vascular clip system (Yaşargil clip) in laparoscopic fibroid enucleation. 61
32500681 2020
8
Clinical analysis of uterine torsion and fibroids in full-term pregnancy: A case report and review of the literature. 61
32485116 2020
9
Effect of preservation time of formalin-fixed paraffin-embedded tissues on extractable DNA and RNA quantity. 61
32567435 2020
10
Myomectomy associated blood transfusion risk and morbidity after surgery. 61
32532486 2020
11
Genetic variant of SRF-rearranged myofibroma with a misleading nuclear expression of STAT6 and STAT6 involvement as 3' fusion partner. 61
32529351 2020
12
Myomectomy for Multiple or Giant Uterine Fibroids. 61
32399487 2020
13
EMA suspends licence for ulipristal acetate for uterine fibroids. 61
32253203 2020
14
Uterine Fibroids Increase the Risk of Thyroid Cancer. 61
32481566 2020
15
Latest Advances in the Laparoscopic Treatment of Uterine Fibroids. 61
32432333 2020
16
Efficacy assessment of acupuncture in improving symptoms of uterine fibroids: A randomized controlled trial. 61
32358379 2020
17
Incidental sonographic detection of bladder cancer in a woman with large uterine fibroids: significance and lessons learned. 61
31945687 2020
18
Hemoperitoneum due to bleeding from a vein overlying a subserous uterine myoma: a case report. 61
32384913 2020
19
Selective progesterone receptor modulators-mechanisms and therapeutic utility. 61
32365199 2020
20
A systematic review of the psychosocial impact of fibroids before and after treatment. 61
32474012 2020
21
Modelling fibroid pathology: development and manipulation of a myometrial smooth muscle cell macromolecular crowding model to alter extracellular matrix deposition. 61
32449756 2020
22
Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. 61
32559602 2020
23
The associations between serum vitamin D, calcium and uterine fibroids in Chinese women: a case-controlled study. 61
32458705 2020
24
Uterine Artery Embolisation for Women with Giant Versus Non-giant Uterine Fibroids: A Systematic Review and Meta-analysis. 61
31792586 2020
25
The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids. 61
32423112 2020
26
Effect of oral consumption of vitamin D on uterine fibroids: A randomized clinical trial. 61
32379687 2020
27
Precision Surgery in Obstetrics and Gynecology: Surgical Approaches for Various Uterine Fibroids. 61
32399484 2020
28
Primary paediatric chest wall tumours necessitating surgical management. 61
32159373 2020
29
Solitary intramuscular myofibroma in an adult: Case report and MR imaging findings. 61
32531695 2020
30
Analgesic use at ovulation and implantation and human fertility. 61
31738897 2020
31
[Study of integrative evidence chain in clinical trial of Guizhi Fuling Capsules based on "Yibing Tongzhi" in clinical applications]. 61
32495585 2020
32
The Focused Ultrasound Myoma Outcome Study (FUMOS); a retrospective cohort study on long-term outcomes of MR-HIFU therapy. 61
32040725 2020
33
Hysteroscopic treatment of submucosal fibroids in perimenopausal women: when, why, and how? 61
32410475 2020
34
Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. 61
31646908 2020
35
Extended Endonasal Endoscopic Complete Resection of a Solitary Intraorbital Myofibroma: A Case Report and Literature Review. 61
31678317 2020
36
Association between maternal anemia at admission for delivery and adverse perinatal outcomes. 61
32238782 2020
37
Diagnosing adenomyosis: an integrated clinical and imaging approach. 61
32097456 2020
38
Anti-Uterine Fibroid Effect of Standardized Labisia Pumila Var. Alata Extracts In Vitro and in Human Uterine Fibroid Cancer Xenograft Model. 61
32334454 2020
39
Pigment epithelium derived factor as a novel multi-target treatment for uterine fibroids. 61
32532667 2020
40
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research. 61
31689495 2020
41
Coexistence of Conventional Leiomyoma, Fumarate Hydratase-deficient Atypical Leiomyoma, and Perivascular Epithelioid Cell Tumor in a Uterus: A Case Study. 61
32265359 2020
42
Twin pregnancies with uterine fibroids are not at increased risk for obstetric complications: single center cohort study. 61
32295544 2020
43
Invasive Procedural Treatments for Symptomatic Uterine Fibroids: A Cost Analysis. 61
32360526 2020
44
Epidemiology and management of uterine fibroids. 61
31960950 2020
45
The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside. 61
32344726 2020
46
Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. 61
31678093 2020
47
Intra-abdominal haemorrhage from uterine fibroids: a systematic review of the literature. 61
32293414 2020
48
Activation of β-Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids. 61
31761932 2020
49
High-throughput sequencing study of the effect of transabdominal hysterectomy on intestinal flora in patients with uterine fibroids. 61
32299359 2020
50
YAP/TAZ are Activated by Mechanical and Hormonal Stimuli in Myometrium and Exhibit Increased Baseline Activation in Uterine Fibroids. 61
32056132 2020

Variations for Myofibroma

Expression for Myofibroma

Search GEO for disease gene expression data for Myofibroma.

Pathways for Myofibroma

Pathways related to Myofibroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.78 MYOG DES CD34

GO Terms for Myofibroma

Biological processes related to Myofibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tissue homeostasis GO:0001894 9.37 PDGFRB CD34
2 mRNA transcription by RNA polymerase II GO:0042789 9.32 SRF MYOG
3 hematopoietic stem cell proliferation GO:0071425 9.26 ETV6 CD34
4 cardiac myofibril assembly GO:0055003 9.16 SRF PDGFRB
5 negative regulation of pri-miRNA transcription by RNA polymerase II GO:1902894 8.96 SRF RELA
6 response to hydrogen peroxide GO:0042542 8.8 RELA PDGFRB MB

Molecular functions related to Myofibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin DNA binding GO:0031490 8.8 SRF RELA MYOG

Sources for Myofibroma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....